Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jul 1;15(7):1007-1014.
doi: 10.2215/CJN.13861119. Epub 2020 Jun 11.

Urinary Lithogenic Risk Profile in ADPKD Patients Treated with Tolvaptan

Matteo Bargagli  1   2 , Nasser A Dhayat  3 , Manuel Anderegg  3 , Mariam Semmo  3 , Uyen Huynh-Do  3 , Bruno Vogt  3 , Pietro Manuel Ferraro  1   2 , Daniel G Fuster  3
Affiliations

Urinary Lithogenic Risk Profile in ADPKD Patients Treated with Tolvaptan

Matteo Bargagli et al. Clin J Am Soc Nephrol. .

Abstract

Background and objectives: Nephrolithiasis is a common health problem in autosomal dominant polycystic kidney disease (ADPKD) and significantly contributes to patient morbidity. Recently, Tolvaptan has been introduced for the treatment of ADPKD, but whether it is associated with alterations of the urinary lithogenic risk profile remains unknown.

Design, setting, participants, & measurements: We conducted an analysis of participants enrolled in the Bern ADPKD registry, a prospective observational cohort study. Twenty-four-hour urine analyses were performed at baseline and then at yearly follow-ups. Relative supersaturation ratios for calcium oxalate, brushite, and uric acid were calculated with the program EQUIL2. Unadjusted and multivariable mixed-effects linear regression models, adjusted for age, sex, body mass index, eGFR, net acid excretion, and height-adjusted total kidney volume, were used to assess the association of Tolvaptan with urinary parameters relevant for kidney stone formation. The maximum individual follow-up time was 3 years, median follow-up time 1.9 years, and cumulative follow-up time 169 years.

Results: In total, 125 participants (38 with and 87 without Tolvaptan treatment) were included in the analysis. In multivariable analysis, Tolvaptan treatment was associated [adjusted estimate of the difference between Tolvaptan and no Tolvaptan; 95% confidence interval (CI)] with lower urine relative supersaturation ratios for calcium oxalate (-0.56; 95% CI, -0.82 to -0.3; P<0.001), brushite (-0.33; 95% CI, -0.54 to -0.11; P=0.004), and uric acid (-0.62; 95% CI, -0.88 to -0.37; P<0.001), and with higher urine citrate in mmol/mmol creatinine per day (0.25; 95% CI, 0.05 to 0.46; P=0.02) and calcium in mmol/mmol creatinine per day (0.31; 95% CI, 0.09 to 0.53; P=0.006) excretion. In addition, Tolvaptan treatment was associated with lower net acid excretion in mEq/mmol creatinine per day (-0.54; 95% CI, -0.90 to -0.17; P=0.004) and higher net gastrointestinal alkali absorption in mEq/mmol creatinine per day (0.57; 95% CI, 0.26 to 0.88; P<0.001).

Conclusions: Tolvaptan treatment is associated with a significantly improved urinary lithogenic risk profile in patients with ADPKD.

Keywords: ADPKD; alkalies; autosomal dominant; body mass index; calcium oxalate; calcium phosphate; citric acid; cohort studies; creatinine; dibasic; dihydrate; follow-up studies; glomerular filtration rate; kidney calculi; kidney stones; linear models; polycystic kidney; prospective studies; tolvaptan; uric acid.

PubMed Disclaimer

Figures

None
Graphical abstract
Figure 1.
Figure 1.
Relative supersaturation ratios at baseline and at 1-year follow-up. Relative supersaturation ratios for calcium oxalate (A), brushite (B), and uric acid (C) in participants with or without Tolvaptan treatment at follow-up. All participants were Tolvaptan-naïve at baseline. Baseline: left side of panel, 1-year follow-up: right side of panel.
See this image and copyright information in PMC

Comment in

References

    1. Reule S, Sexton DJ, Solid CA, Chen S-C, Collins AJ, Foley RN: ESRD from autosomal dominant polycystic kidney disease in the United States, 2001-2010. Am J Kidney Dis 64: 592–599, 2014. - PMC - PubMed
    1. Kramer A, Pippias M, Noordzij M, Stel VS, Andrusev AM, Aparicio-Madre MI, Arribas Monzón FE, Åsberg A, Barbullushi M, Beltrán P, Bonthuis M, Caskey FJ, Castro de la Nuez P, Cernevskis H, De Meester J, Finne P, Golan E, Heaf JG, Hemmelder MH, Ioannou K, Kantaria N, Komissarov K, Korejwo G, Kramar R, Lassalle M, Lopot F, Macário F, Mackinnon B, Pálsson R, Pechter Ü, Piñera VC, Santiuste de Pablos C, Segarra-Medrano A, Seyahi N, Slon Roblero MF, Stojceva-Taneva O, Vazelov E, Winzeler R, Ziginskiene E, Massy Z, Jager KJ: The European renal association - European dialysis and transplant association (ERA-EDTA) registry annual report 2016: A summary. Clin Kidney J 12: 702–720, 2019. - PMC - PubMed
    1. Porath B, Gainullin VG, Cornec-Le Gall E, Dillinger EK, Heyer CM, Hopp K, Edwards ME, Madsen CD, Mauritz SR, Banks CJ, Baheti S, Reddy B, Herrero JI, Bañales JM, Hogan MC, Tasic V, Watnick TJ, Chapman AB, Vigneau C, Lavainne F, Audrézet M-P, Ferec C, Le Meur Y, Torres VE, Harris PC; Genkyst Study Group, HALT Progression of Polycystic Kidney Disease Group; Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease : Mutations in GANAB, encoding the glucosidase IIα subunit, cause autosomal-dominant polycystic kidney and liver disease. Am J Hum Genet 98: 1193–1207, 2016. - PMC - PubMed
    1. Chapman AB, Devuyst O, Eckardt K-U, Gansevoort RT, Harris T, Horie S, Kasiske BL, Odland D, Pei Y, Perrone RD, Pirson Y, Schrier RW, Torra R, Torres VE, Watnick T, Wheeler DC; Conference Participants : Autosomal-dominant polycystic kidney disease (ADPKD): Executive summary from a kidney disease: Improving global outcomes (KDIGO) controversies conference. Kidney Int 88: 17–27, 2015. - PMC - PubMed
    1. Cornec-Le Gall E, Torres VE, Harris PC: Genetic complexity of autosomal dominant polycystic kidney and liver diseases. J Am Soc Nephrol 29: 13–23, 2018. - PMC - PubMed

Publication types

MeSH terms